Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

NCT ID: NCT00741273

Last Updated: 2014-08-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2009-06-30

Brief Summary

This study will evaluate the safety and pharmacokinetics of two doses of orally administered Proellex® in female patients with impaired hepatic function and healthy volunteers with normal hepatic function.

Detailed Description

16 subjects will be allocated to 2 groups. The test group will consist of 8 female patients with moderately impaired hepatic function meeting the Child-Pugh Class B severity criteria, while the control group will consist of 8 healthy female adult volunteers. During Stage I, all subjects will receive a single oral dose of 25mg of Proellex® (fasting state) and be followed in a Clinical Research Unit (CRU) for about three days. Only subjects who do not experience serious adverse events (SAEs) or adverse events (AEs) that are determined by Investigator to be possibly, probably or definitely related to the treatment will participate in Stage II. The dose will be increased to a single dose of 50mg of Proellex® (fasting state) and subjects will be followed in a Clinical Research Unit (CRU) for about three days. Subjects will undergo blood draws at several time points.

Conditions

Impaired Liver Function

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: NONE

Study Groups

Proellex 25 mg healthy

Proellex 25 mg in healthy females

Group Type: EXPERIMENTAL

Proellex

Intervention Type: DRUG

Proellex 25 mg capsule, single dose

Proellex 25 mg Impaired

Proellex 50 mg in hepatically impaired females

Group Type: EXPERIMENTAL

Proellex

Intervention Type: DRUG

Proellex 25 mg capsule, single dose

Interventions

Proellex

Proellex 25 mg capsule, single dose

Intervention Type: DRUG

Other Intervention Names

Telapristone acetate

Eligibility Criteria

Inclusion Criteria

• Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
• Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive, are preferred; however, subjects up to 62 years old, inclusive, may participate;
• Subjects with moderate hepatic insufficiency must meet the Class B level of the Child-Pugh criteria;
• Subjects must have evidence of stable hepatic impairment;
• If on medications for treatment of the complications of liver disease, and other concomitant chronic illnesses, subjects must have been taking the medications at a stable dose for at least 10 days prior to the first dosing date and are then to be continued at the same dose for the duration of the study;
• Non-smokers are preferred, but light to moderate smoking will be allowed (no more than 10 cigarettes/day)
• Subject is willing to remain in the clinic for the screening visit and for two treatment visits (approximately 3 days for each treatment visit);

Exclusion Criteria

• Past or present history of an allergic reaction to the formulations administered in this study, or in the opinion of the Investigator, suggesting an increased potential for an adverse hypersensitivity;
• Pregnant or lactating females, or women who are attempting or expecting to become pregnant at any time during the study or one month after the study;
• A physical illness within three (3) months of the study that would interfere with the study as determined by the Investigator;
• An acute illness within five (5) days of study medication administration;
• Positive urine drug screen at the screening visit based on laboratory testing;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 62 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Repros Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andre van As, MD, PhD

Role: STUDY_DIRECTOR

Repros Therapeutics Inc.

Locations

Clinical Pharmacology of Miami, Inc.

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Countries

United States

Other Identifiers

ZP-005

Identifier Type: -

Identifier Source: org_study_id